Sidney Lupkin

You bet.

You bet.

You bet.

Novo Nordisk is joining its competitor Eli Lilly and offering its obesity drug direct-to-consumers at a discount. Lilly started offering vials of its weight loss drug Zepbound online last summer. The direct-to-consumer model is fairly new to the pharmaceutical industry, but it wouldn't work for every medicine, says Dr. Ben Rome, a health policy researcher at Brigham and Women's Hospital in Boston.

Novo Nordisk is joining its competitor Eli Lilly and offering its obesity drug direct-to-consumers at a discount. Lilly started offering vials of its weight loss drug Zepbound online last summer. The direct-to-consumer model is fairly new to the pharmaceutical industry, but it wouldn't work for every medicine, says Dr. Ben Rome, a health policy researcher at Brigham and Women's Hospital in Boston.

According to the Centers for Disease Control and Prevention, two in five American adults is obese. Sydney Lepkin, NPR News.

According to the Centers for Disease Control and Prevention, two in five American adults is obese. Sydney Lepkin, NPR News.